NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Molina Healthcare, Inc. (“Molina” or “the Company”) (NYSE: MOH) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Molina sec ...

LOS ANGELES, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming December 2, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH) securities between February 5, 2025 and July 23, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR MOLINA INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO ...

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Molina business and prospects, resulting in its stock trading at inflated prices. ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Molina Healthcare, Inc. securities between February 5, 2025, and July 23, 2025, due to undisclosed adverse facts affecting the company's financial guidance and operations [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Molina Healthcare failed to disclose material adverse facts regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [5]. - The lawsuit alleges that Molina's near-term growth relied on a lack of utilization of various health services, which was not communicated to investors [5]. - As a result of these undisclosed facts, Molina's financial guidance for fiscal year 2025 was likely to be cut, leading to misleading positive statements about the company's business and prospects [5]. Group 2: Participation Information - Investors who purchased Molina securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6].

Core Points - ClaimsFiler reminds investors of the deadline to file lead plaintiff applications in a securities class action lawsuit against Molina Healthcare, Inc. for the Class Period from February 5, 2025, to July 23, 2025 [1] - The lawsuit alleges that Molina Healthcare and certain executives failed to disclose material information, violating federal securities laws [3] - Following the company's second-quarter financial results announcement on July 23, 2025, which included an 8% year-over-year decrease in GAAP net income and a cut in full-year earnings guidance, Molina's share price dropped by 16.84% [4] Company Information - Molina Healthcare reported a GAAP net income of $4.75 per diluted share for Q2 2025, down from the previous year, and adjusted earnings expectations for the full year 2025 to be no less than $19.00 per diluted share due to challenging medical cost trends [4] - The case is officially titled Hindlemann v. Molina Healthcare, Inc., et al., No. 2:25-cv-09461 [5] Investor Resources - ClaimsFiler provides a platform for retail investors to recover funds from securities class action settlements, offering free registration, portfolio data uploads, and inquiries for case evaluations [6]

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming December 2, 2025 to deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Molina Healthcare, Inc. ("Molina†or the "Company†) (NYSE: MOH) securities between February 5, 2025 and July 23, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MOLINA HEALTHCARE, INC. (MOH), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE. ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action set for December 2, 2025 [3]. Group 1: Allegations Against Molina - The complaint alleges that Molina and its executives made false or misleading statements and failed to disclose material adverse facts regarding the company's medical cost trend assumptions [5]. - It is claimed that Molina was experiencing a dislocation between premium rates and medical costs, which affected its near-term growth [5]. - The financial guidance for fiscal year 2025 was likely to be cut due to these issues, and positive statements made by the defendants were misleading [5]. Group 2: Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below prior expectations, leading to a 10.2% cut in full-year earnings guidance from at least $24.50 per share to a range of $21.50 to $22.50 [6]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025 [6]. - On July 23, 2025, Molina further slashed its full-year earnings guidance, reporting a GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year over year, and cutting its full-year adjusted earnings guidance to no less than $19.00 per diluted share [7][8]. - This led to a significant drop in Molina's stock price by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [8].

Core Viewpoint - Molina Healthcare, Inc. is facing legal action due to allegations of making materially false and misleading statements regarding its financial outlook and medical cost trends during the specified class period [2][3]. Allegations - Molina reported Q2 2025 adjusted EPS of approximately $5.50, which was below prior expectations, leading to a 10.2% cut in its full-year earnings guidance at the midpoint [3] - The company warned that medical cost pressures would continue through the second half of the year, contributing to a decline in its stock price [3] - On July 23, 2025, Molina announced Q2 GAAP net income of $4.75 per diluted share, an 8% decrease year over year, and further reduced its full-year adjusted earnings expectations to no less than $19.00 per share due to a challenging medical cost trend environment [4] - Following this announcement, Molina's stock fell nearly 17% [4] Financial Guidance Issues - Molina's medical cost trend assumptions were found to be inaccurate [9] - There was a dislocation between premium rates and medical cost trends [9] - Near-term growth was dependent on reduced utilization of behavioral health, pharmacy, and inpatient/outpatient services [9] - Consequently, Molina's FY 2025 guidance was likely to be cut [9]

Core Viewpoint - A lawsuit has been filed against Molina Healthcare, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - Investors have until December 2, 2025, to request to lead the case, which is pending in the U.S. District Court for the Central District of California [2]. - The lawsuit is titled Hindlemann v. Molina Healthcare, Inc., et al., No. 25-cv-9461 [2]. Group 2: Company Background - Molina Healthcare is a health insurance company providing managed healthcare services to low-income individuals under Medicaid and Medicare programs [3]. - The company previously claimed a "solid" earnings growth profile heading into 2025 and stated it was monitoring utilization patterns to mitigate healthcare cost inflation [3]. Group 3: Financial Performance and Stock Impact - On July 7, 2025, Molina reported Q2 2025 adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - The company cut its guidance for expected adjusted earnings per share by 10.2% to a range of $21.50 to $22.50 per share [4]. - Following further revelations on July 23, 2025, Molina adjusted its full-year 2025 earnings expectation to no less than $19.00 per diluted share, citing a challenging medical cost trend environment [4]. - The stock price fell by $32.03 per share, or 16.8%, from $190.25 on July 23, 2025, to $158.22 on July 24, 2025, in response to these announcements [4].

Core Insights - The current investment landscape highlights persistent skepticism towards the Energy and Financial sectors, which are identified as undervalued [1] Financial Sector Summary - Bank of New York Mellon (BK) has an Acquirer's Multiple (AM) of 2.1 and a free cash flow (FCF) yield of 3.2%, while Synchrony Financial (SYF) shows an AM of 2.2 and an exceptional FCF yield of 37.2%, indicating a strong deep-value case in financials despite market concerns over credit and interest-rate risks [2] - The market's pricing reflects ongoing credit and interest-rate risks, which disciplined value investors may view as opportunities [2] Energy Sector Summary - Petrobras (PBR) trades at an AM of 4.1 with a 36.4% FCF yield, and Equinor (EQNR) has an AM of 2.7 with an 11.4% FCF yield and a near-double-digit dividend payout, showcasing a disconnect between strong cash generation and market doubts about fossil fuel demand [3] - Both Petrobras and Equinor maintain strong balance sheets and shareholder distributions, yet their valuations remain low [3] Healthcare Sector Summary - Molina Healthcare (MOH) appears with an AM of 6.0 and a 3.9% FCF yield, indicating consistent profitability and steady operating income growth, which is appealing in uncertain markets [4] Market Implications - The convergence of multiple sectors at the top of value screens signals broad-based pessimism regarding future earnings durability, particularly in Energy and Finance due to transition risks and credit concerns [5] - The presence of a healthcare company suggests selective investment opportunities beyond typical cyclical sectors [5] Conclusion - The value landscape is dominated by Energy and Financials, which offer high free cash flow and strong capital returns amidst market skepticism, presenting opportunities for patient contrarian investors [6] - Select healthcare names provide diversification, indicating fertile ground for disciplined value seekers in a cautious market environment [6]